Expert Interview
A Second Opinion: Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Ticker(s): RGNX, FDMT, ABBV, RHHBY, REGNInstitution: Duke
- Assistant Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery at Duke.
- Manages 500 patients with geographic atrophy.
- Studies the biology, diagnosis and treatment of macular edema, and I am involved in basic laboratory science, ocular imaging analysis and clinical trials of new medications.
Please describe your practice as a clinician: how many patients with wet AMD do you treat on a yearly basis?
Could you walk us through the standard of care, and tell us a bit about the most promising upcoming treatments, or interesting clinical trials in this space.
What is your opinion on the potential of gene therapies for wet-AMD patients?
What is your view on the route of administration for ABBV-RGX-314?
Added By: ben_adminWill the cost of gene therapies be a big barrier for wet-amd adoption?
Added By: ben_adminRank your excitement for ABBV-RGX-314 on a scale of 1-10?
Added By: ben_adminWould you suggest any novel endpoints in the Phase 3 program, such as reduction in VEGF use? Any other endpoints based on potential payer responses?
Added By: ben_adminDo you have a patient profile in mind for who would be an ideal candidate for gene therapy? How much do you think prior authorizations and other payer tactics will interfere with access for these patients?
Added By: ben_adminPlease ask about VEGF TKIs and the OPT VEGF-C/D trap if you have time.
Added By: ben_adminWhat long term safety data would you like to see collected in Phase 3, LTEs or REMS studies?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
